Business
Project update for AI model of RSV data
Project update for AI model of RSV data.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n Poolbeg Pharma Plc\n \n \n \n \n \n \n \n OneThree Biotech completes build and optimisation of AI model for RSV data - results to come in H2\n \n \n \n \n \n \n \n First time AI used to model RSV with complete longitudinal disease data\n \n \n \n \n \n \n 27 June 2022 -\n \n \n Poolbeg Pharma\n \n \n (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that, further to its announcement in\n \n \n February 2022\n \n \n , Artificial Intelligence ('AI') partner\n \n \n OneThree Biotech\n \n \n , Inc., has completed the build and optimisation of a tailored AI model of Poolbeg's Respiratory Syncytial Virus ('RSV') human challenge data and can now commence its analysis, with results expected in Q4 2022.\n \n \n \n \n \n Key Highlights:\n \n \n \n \n \n \n •\n \n \n \n \n Build and optimisation phase of AI model to identify RSV drug targets and treatments completed - results expected in Q4 2022\n \n \n \n \n \n \n •\n \n \n \n \n Model is uniquely tailored to use Poolbeg's human challenge trial data of RSV\n \n \n \n \n \n \n •\n \n \n \n \n The Directors believe this is the first time that AI analysis has been used to identify new drug targets and treatments for RSV using human challenge trial data\n \n \n \n \n \n \n •\n \n \n \n \n Process will identify novel drug targets and treatments quicker and in a more cost-efficient manner than previously possible\n \n \n \n \n \n \n \n \n \n The tailored AI model is the platform from which OneThree Biotech and Poolbeg will mine truly unique insights from human challenge trial* derived disease progression data, with the aim of identifying novel drug targets and therapies to treat RSV, a disease which is a significant public health threat.\n \n \n \n \n \n OneThree's clinically validated model has been optimised to harness the unique longitudinal clinical, molecular (e.g. gene and protein expression) and virological data collected during human challenge trials, and includes next generation sequencing data captured daily at all timepoints before, during and after a healthy volunteer has been infected with RSV. The controlled environment of the human challenge trial creates a uniquely clean and complete dataset which is ideally suited ...